ArticleJournal of investigative medicine high impact case reports
Successful Treatment of Double-Positive Rapidly Progressive Glomerulonephritis: A Case Report.
Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this case report, we describe a case of double-positive rapidly progressive glomerulonephritis among the Lebanese population. The patient, a 44-year-old female, presented with anemia and a recurrent right middle lobe pneumonia. She rapidly developed renal failure with her autoimmune workup being positive for both anti-glomerular basement membrane antibodies and anti-neutrophil cytoplasmic antibodies. The patient was successfully treated with plasmapheresis, intravenous cyclophosphamide, and oral prednisone. The patient regained her normal renal function and did not depend on dialysis for renal and overall survival. At 6-month follow-up, the patient is in remission on a steroids taper. As treatment guidelines are still not well established for such unique presentations, this report highlights the importance of early intervention and combined therapy to treat double-positive rapidly progressive glomerulonephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.